Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy

Am J Hematol. 1999 Feb;60(2):164-6. doi: 10.1002/(sici)1096-8652(199902)60:2<164::aid-ajh16>3.0.co;2-4.

Abstract

A human immunodeficiency virus (HIV)-infected individual was first diagnosed with red blood cell aplasia due to B19 parvovirus infection in late 1989. Over the subsequent seven-year period, he received a total of 119 units of red blood cells (RBCs) and intravenous immunoglobulin every 2-3 weeks. In 1996 combination antiretroviral treatment with a protease inhibitor was initiated. He received four more units during the following two months and then required no more transfusions for the subsequent 24 months of follow-up. His CD4 count progressively increased and DNA polymerase chain reaction for parvovirus B19 became undetectable. Aggressive antiretroviral treatment may effectively diminish transfusion requirements among HIV-infected individuals with pure RBC aplasia resulting from parvovirus B19 infection.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Erythrocyte Transfusion
  • HIV Infections / complications*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Lamivudine / therapeutic use
  • Male
  • Parvoviridae Infections / complications*
  • Parvovirus B19, Human*
  • Red-Cell Aplasia, Pure / therapy
  • Red-Cell Aplasia, Pure / virology*
  • Remission Induction
  • Ritonavir / therapeutic use
  • Saquinavir / therapeutic use
  • Zidovudine / therapeutic use

Substances

  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • Lamivudine
  • Zidovudine
  • Saquinavir
  • Ritonavir